February 2017

New Product - Zykadia

Zykadia (ceritinib) is an anaplastic lymphoma kinase (ALK) inhibitor. Ceritinib inhibits autophosphorylation of ALK, ALK mediated phosphorylation of downstream signalling proteins and proliferation of ALK dependent cancer cells both in vitro and in vivo. Zykadia is indicated as monotherapy for the treatment of adult patients with ALK positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or who are intolerant of crizotinib. Note to indication: this indication is approved based on tumour response rates and duration of response. An improvement in survival or disease related symptoms has not been established. Zykadia is available as 150 mg tablets in multipacks (3 packs of 50’s).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au